*ST香雪 reported revenue of ¥0.70B for the period ended 2026-06-30, -14.1% year on year. Net income was ¥-0.25B, a -35.8% net margin on a 32.4% gross margin. The largest revenue line is 中药材 at 64% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.70B | -14.1% |
| Gross profit | ¥0.23B | — |
| Operating income | ¥-0.12B | — |
| Net income | ¥-0.25B | — |
| Gross margin | 32.4% | Net margin -35.8% |
| Revenue Q/Q | -1.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 中药材 | ¥0.45B | 63.6% |
| 医药制造 | ¥0.19B | 26.6% |
| 其它 | ¥0.14B | 19.4% |
| 医药流通 | ¥0.02B | 3.0% |
| 医疗器械 | ¥0.01B | 1.0% |
| 分部间抵销 | ¥-0.10B | -13.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.48B | 67.6% |
| R&D | ¥0.02B | 3.2% |
| SG&A | ¥0.19B | 26.3% |
| Tax & other | ¥0.13B | 18.3% |
| Item | Amount |
|---|---|
| Total assets | ¥6.65B |
| Total liabilities | ¥6.89B |
| Shareholders' equity | ¥-0.24B |
| Equity / assets | -3.6% |
| Operating cash flow | ¥-0.02B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | 36% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
天舟文化 ・ 睿智医药 ・ 世纪瑞尔 ・ 昌红科技 ・ *ST动力 ・ 科泰电源 ・ 瑞凌股份 ・ 安居宝 ・ 新锦动力 ・ 振东制药 ・ 新研股份 ・ 秀强股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies